Direct
NAV (05-Sep-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹67 Cr
Expense Ratio
0.34%
ISIN
INF277KA1BG3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
About this fund
As of 05-Sep-24, it has a Net Asset Value (NAV) of ₹12.51, Assets Under Management (AUM) of 67.01 Crores, and an expense ratio of 0.34%.
- Tata Nifty MidSmall Healthcare Index Fund Direct Growth has given a CAGR return of 25.09% since inception.
- The fund's asset allocation comprises around 100.04% in equities, 0.00% in debts, and -0.04% in cash & cash equivalents.
- You can start investing in Tata Nifty MidSmall Healthcare Index Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+25.09%
— (Cat Avg.)
Portfolio Summaryas of 31st July 2024
| Equity | ₹67.04 Cr | 100.04% |
| Others | ₹-0.02 Cr | -0.04% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹9.03 Cr | 13.48% |
| Lupin Ltd | Equity | ₹6.12 Cr | 9.13% |
| Aurobindo Pharma Ltd | Equity | ₹5.34 Cr | 7.98% |
| Alkem Laboratories Ltd | Equity | ₹3.53 Cr | 5.27% |
| Fortis Healthcare Ltd | Equity | ₹3.46 Cr | 5.17% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.91 Cr | 4.34% |
| Mankind Pharma Ltd | Equity | ₹2.48 Cr | 3.70% |
| Laurus Labs Ltd | Equity | ₹2.42 Cr | 3.61% |
| Ipca Laboratories Ltd | Equity | ₹2.33 Cr | 3.48% |
| Biocon Ltd | Equity | ₹2.13 Cr | 3.18% |
| Abbott India Ltd | Equity | ₹2 Cr | 2.99% |
| Gland Pharma Ltd | Equity | ₹1.95 Cr | 2.92% |
| Syngene International Ltd | Equity | ₹1.94 Cr | 2.90% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.82 Cr | 2.72% |
| Suven Pharmaceuticals Ltd | Equity | ₹1.67 Cr | 2.50% |
| Natco Pharma Ltd | Equity | ₹1.64 Cr | 2.44% |
| Ajanta Pharma Ltd | Equity | ₹1.56 Cr | 2.32% |
| Dr. Lal PathLabs Ltd | Equity | ₹1.5 Cr | 2.24% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.47 Cr | 2.19% |
| Piramal Pharma Ltd | Equity | ₹1.42 Cr | 2.12% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹1.39 Cr | 2.07% |
| Global Health Ltd | Equity | ₹1.37 Cr | 2.04% |
| Granules India Ltd | Equity | ₹1.13 Cr | 1.69% |
| Narayana Hrudayalaya Ltd | Equity | ₹1.12 Cr | 1.68% |
| Poly Medicure Ltd | Equity | ₹1.12 Cr | 1.67% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.86 Cr | 1.28% |
| Sanofi India Ltd | Equity | ₹0.79 Cr | 1.17% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.78 Cr | 1.17% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.74 Cr | 1.10% |
| Metropolis Healthcare Ltd | Equity | ₹0.72 Cr | 1.07% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹0.28 Cr | 0.42% |
| Net Current Liabilities | Cash - Collateral | ₹-0.09 Cr | 0.13% |
| A) Repo | Cash - Repurchase Agreement | ₹0.06 Cr | 0.10% |
Allocation By Market Cap (Equity)
Large Cap Stocks
3.70%
Mid Cap Stocks
67.01%
Small Cap Stocks
28.90%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹66.76 Cr | 99.62% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Kapil Menon
Since April 2024
Additional Scheme Detailsas of 31st July 2024
ISIN | INF277KA1BG3 | Expense Ratio | 0.34% | Exit Load | No Charges | Fund Size | ₹67 Cr | Age | 26 Apr 2024 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | Nifty MidSmall Healthcare Index (TRI) |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
- If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
- If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
- Holding the units: No tax is applicable as long as you continue to hold the units.
Dividend Taxation:
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹539.42 Cr | 45.5% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹539.42 Cr | 44.6% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹397.46 Cr | 61.6% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹587.30 Cr | 42.9% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1683.73 Cr | 39.1% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1000.66 Cr | 49.6% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹587.30 Cr | 43.7% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹397.46 Cr | 62.6% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1683.73 Cr | 39.9% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1000.66 Cr | 48.7% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Tata Nifty MidSmall Healthcare Index Fund Direct Growth?
What is the portfolio composition of Tata Nifty MidSmall Healthcare Index Fund Direct Growth?
Who manages the Tata Nifty MidSmall Healthcare Index Fund Direct Growth?
- Kapil Menon
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.